Matsui Yumi, Kobayashi Naoki, Nishikawa Makiya, Takakura Yoshinobu
Department of Biopharmaceutics and Drug Metabolism, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan.
Pharm Res. 2005 Dec;22(12):2091-8. doi: 10.1007/s11095-005-8178-8. Epub 2005 Oct 1.
RNA interference (RNAi) is a powerful tool for silencing gene expression posttranscriptionally. The purpose of this study was to examine whether in vivo RNAi can be induced against endogenous mdr1a/1b in adult mice and to assess the feasibility of generating P-glycoprotein (P-gp) knockdown mice based on RNAi by a very simple intravenous injection of synthetic small interfering RNA (siRNAs) or siRNA-expressing plasmid DNAs.
The targeted sequences for silencing mdr1a specifically or mdr1a/1b simultaneously were examined in an in vitro study using a mouse colon carcinoma cell line, colon26 cells, in culture. Mice were repeatedly treated with intravenous synthetic siRNAs or siRNA-expressing plasmid DNAs in naked form administered via a large-volume and high-speed injection, i.e., the hydrodynamics-based procedure. The amount of targeted mRNA and P-gp in the liver were determined by real-time polymerase chain reaction and Western blot analysis, respectively.
Among several targeted sequences, two and one optimized sequences were selected for mdr1a and mdr1a/1b, respectively, in the in vitro study. Following administration of synthetic siRNAs or siRNA-expressing plasmid DNAs directed against mdr1a, the mRNA level in the liver was significantly reduced to approximately 50-60% of that in control mice. Furthermore, a slight reduction was observed at the protein level. Similar results were obtained in the experiments using siRNA-expressing pDNA directed against mdr1a/1b.
Our results demonstrate that sequence-specific suppression of mdr1 gene expression is possible at the mRNA level as well as the protein level in mice following intravenous delivery of siRNA effectors.
RNA干扰(RNAi)是一种在转录后沉默基因表达的强大工具。本研究的目的是检测成年小鼠体内是否能诱导针对内源性mdr1a/1b的RNAi,并评估通过非常简单的静脉注射合成小干扰RNA(siRNA)或表达siRNA的质粒DNA来生成P-糖蛋白(P-gp)敲低小鼠的可行性。
在体外研究中,使用培养的小鼠结肠癌细胞系colon26细胞,检测特异性沉默mdr1a或同时沉默mdr1a/1b的靶向序列。通过基于流体动力学的方法,即大容量高速注射,对小鼠反复静脉注射裸露形式的合成siRNA或表达siRNA的质粒DNA。分别通过实时聚合酶链反应和蛋白质印迹分析测定肝脏中靶向mRNA和P-gp的量。
在体外研究中,分别为mdr1a和mdr1a/1b选择了两个和一个优化序列。给予针对mdr1a的合成siRNA或表达siRNA的质粒DNA后,肝脏中的mRNA水平显著降低至对照小鼠的约50 - 60%。此外,在蛋白质水平观察到轻微降低。在使用针对mdr1a/1b的表达siRNA的pDNA的实验中也获得了类似结果。
我们的结果表明,在静脉递送siRNA效应物后,小鼠体内mdr1基因表达在mRNA水平和蛋白质水平上都可以进行序列特异性抑制。